Velocity Clinical Research partnered with Palantir Technologies for streamlining and automating payment reconciliation processes in trials ...

UroMems is set to enter the pivotal trial phase with its device for treating stress urinary incontinence (SUI).

Novartis is stopping the development of ianalumab in hidradenitis suppurativa (HS) after a Phase IIb proof-of-concept trial failed to meet its primary endpoint.

The UK MHRA has granted approval for Cybin to initiate the EMBRACE study to assess CYB003 for the adjunctive treatment of MDD.

With the aim of being the largest life sector by 2035 behind only the US and China, the UK government is ramping up commercialisation.

The growing prevalence of prediabetes among children and adolescents suggests that unhealthy, inactive lifestyles are increasing in the US.

World Brain Day draws attention to the increasing prevalence of Alzheimer's and PD in an ageing global population.

Aptar Pharma has announced the acquisition of Mod3 Pharma's clinical trial materials manufacturing capabilities from SWK Holdings.

Eli Lilly hopes donanemab will soon nab the second Alzheimer’s drug approval of 2023. Here’s a look at how donanemab stacks up to lecanemab.

OKYO Pharma has reported encouraging top-line outcomes from the randomised Phase II trial of urcosimod to treat NCP.

SPRIM PRO and ObvioHealth have announced an expansion of their partnership to provide a fully integrated trial solution.

Hengrui Pharma and Kailera Therapeutics have reported positive topline data from the former’s Phase III trial (HRS9531-301) of HRS9531.